5 billion exemplifies Novartis' aggressive bids for strong strategic assets. Further, the much larger acquisition of Alcon in the rapidly growing eye-care market for just over $50 billion shows that the company will aggressively reinvest capital
The European regulator approves Sandoz' (NYSE: NVS ) Simbrinza eye drops suspension ( brinzolamide 10 mg/ml and brimonidine tartrate 2mg/ml) to decrease intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for which monotherapy provides insufficient IOP ...
ZURICH, July 28 (Reuters) - Swiss pharmaceutical group Novartis said the European Commission has approved its eyecare unit Alcon 's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease.
conditions. Novartis' eye care division Alcon has entered into an agreement with ..... solutions to big global problems, so that Alcon can properly utilize the opportunity ..... technology. The technology could enhance Alcon 's eye care pipeline and strengthen
Chief Executive Officer Harry Kirsch - Chief Financial Officer David Epstein - Head of the Pharma Division Jeff George - Alcon Richard Francis - Sandoz Samir Shah - Global Head, IR Analysts Graham Parry - Bank of America Merrill Lynch Richard Vosser
1.0%); Pharmaceuticals: $8,199M (+1.0%); Alcon : $2,817M (+3.0%); Sandoz: $2,331M (+5 ..... Pharmaceuticals Growth: in line with 2013 (unch); Alcon Growth: Mid to high-single digit (unch); Sandoz Growth
psoriasis drug AIN457 and hypertension drug LCZ696) will largely offset the patent losses. Novartis' eye-care business ( Alcon ) and generics unit (Sandoz) should help mitigate the patent losses as well.
Novartis (NYSE: NVS ) unit Alcon enters an agreement with Google (NASDAQ: GOOG ) to in-license its "smart lens" technology for all ocular medical uses. Alcon intends to develop the technology to transform eye care and ultimately
ZURICH, July 15 (Reuters) - Novartis said it has struck an agreement with Google for its eyecare unit Alcon to license the American technology firm's smart lens technology for medical use.
be facing increased competition over the next several quarters. Outside the drug group, both the eye-care division of Alcon and the generic division of Sandoz posted gains of 6% and 4%, respectively, versus the prior-year period. We expect